Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)
← catalyst calendarNCT07123155 · readout in 354 d
Sponsored by Shionogi (industry) · 4507.T — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
45estimated
Sites
28
Countries
Belgium, Denmark, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-30 | actual | When the study began enrolling |
| Primary completion | 2027-08-08 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-08 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pompe Disease
Interventions
- Drug: S-606001
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange From Baseline in Percent Forced Vital Capacity (%FVC) at Week 52
measured Baseline, Week 52
Permalink · 4507.T's whole pipeline · Catalyst calendar · Every registered study · What changed